Mark Cuban Cost Plus Drug Co. will lead research teams laying the groundwork for a domestically manufactured ibogaine product, part of an HHS effort to develop the psychedelic as a potential treatment for post-traumatic stress disorder and other serious mental illnesses, including among veterans. HHS committed up to $4.9 million to the effort through the Advanced Research Projects Agency for Health, the department announced Nov. 12. The Cost Plus-led teams will build the regulatory, clinical, chemical and engineering foundation for a single-molecule ibogaine hydrochloride product. Separately, Beond will generate clinical… Originally published in Becker’s Hospital Review. Read More
Mark Cuban’s Cost Plus to develop US-made ibogaine in HHS push
Integrated Psychiatric Consultants
Office Hours:Mon-Fri, 9 a.m. - 5 p.m. CT